<DOC>
	<DOCNO>NCT01708616</DOCNO>
	<brief_summary>This single-center , randomize , double-blind , two-period crossover study evaluate safety , tolerability , pharmacokinetics pharmacodynamic effect combination multiple dose RO5285119 single dose risperidone healthy volunteer . Subjects randomize one 4 treatment sequence two period receive multiple dos RO5285119 plus single dose risperidone risperidone placebo multiple dos RO5285119 placebo plus single dose risperidone risperidone placebo , washout period approximately 3 week treatment period . Anticipated time study 12 week ( screen study completion ) .</brief_summary>
	<brief_title>A Study Combination Multiple Doses RO5285119 With Single Dose Risperidone Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Risperidone</mesh_term>
	<criteria>Healthy male female adult , 18 50 year age inclusive Healthy status define absence evidence active chronic disease follow detailed medical surgical history physical examination include vital sign , 12lead ECG , hematology , blood chemistry , serology urinalysis Body mass index ( BMI ) 18 30 kg/m2 inclusive Women postmenopausal surgically sterile Male subject must use barrier method contraception duration study 3 month last dosing Suspicion regular consumption drug abuse , history drug alcohol abuse Positive hepatitis B , hepatitis C HIV infection History clinically significant hypersensitivity allergic reaction Disorders central nervous system , include psychiatric disorder , behavioural disturbance , cerebrovascular event , depression , bipolar disorder , migraine , Parkinson Regular smoker ( &gt; 5 cigarette , &gt; 3 pipefulls , &gt; 3 cigar per day ) Administration investigational drug device within 3 month prior first dose Hypersensitivity risperidone excipients Any known contraindication risperidone state SmPC</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>